ACUTE KIDNEY INJURY TREATMENT MARKET ANALYSIS

Key Developments

• In February 2024, CalciMedica, Inc., a clinical-stage biopharmaceutical company, had received FDA clearance for its Investigational New Drug (IND) application for Auxora, a small molecule inhibitor targeting Orai1-containing CRAC channels. The company plans to evaluate Auxora in a Phase 2 trial, named KOURAGE, for acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). The trial is expected to begin in the first half of 2024, with data anticipated in 2025.
• In December 2023, Mission Therapeutics had received FDA approval for its Investigational New Drug (IND) application for MTX652, its lead asset. This approval allows the company to move forward with its planned Phase II clinical trial in the US. MTX652 is a first-in-class therapeutic targeting mitophagy, developed by the clinical-stage biotech.